kneat.com (TSE:KSI) Reaches New 12-Month High – Should You Buy?

kneat.com, inc. (TSE:KSI)’s stock price reached a new 52-week high on Wednesday . The stock traded as high as C$6.53 and last traded at C$6.45, with a volume of 128055 shares changing hands. The stock had previously closed at C$6.39.

Analysts Set New Price Targets

KSI has been the topic of a number of recent analyst reports. Cibc World Mkts upgraded kneat.com to a “strong-buy” rating in a report on Tuesday, October 29th. CIBC set a C$6.00 price target on shares of kneat.com and gave the company an “outperform” rating in a research report on Tuesday, October 29th.

kneat.com Stock Down 0.5 %

The company has a current ratio of 1.47, a quick ratio of 1.50 and a debt-to-equity ratio of 95.14. The firm’s fifty day moving average price is C$5.86 and its 200-day moving average price is C$5.10. The company has a market cap of C$543.52 million, a price-to-earnings ratio of -39.50, a price-to-earnings-growth ratio of 597.67 and a beta of 1.08.

kneat.com (TSE:KSI) last posted its earnings results on Wednesday, November 6th. The company reported C$0.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of C($0.05) by C$0.06. kneat.com had a negative return on equity of 51.13% and a negative net margin of 31.19%. During the same period in the previous year, the business earned ($0.05) earnings per share. Sell-side analysts predict that kneat.com, inc. will post -0.12 earnings per share for the current year.

kneat.com Company Profile

kneat.com, inc., together with its subsidiaries, designs, develops, and supplies software for data and document management within regulated environments in North America, Europe, and the Asia Pacific. The company offers the Kneat Gx platform, a configurable off-the-shelf application focused on validation lifecycle management and testing for biotechnology, pharmaceutical, and medical device manufacturing industries.